Aurora CEO Miguel Martin characterized the move as a tactical effort to pressure investors into a short-term exit, arguing that the bid fails to capture the true value of the company’s EU-GMP manufacturing facilities and its established medical platform. The offer, which includes a mix of Curaleaf subordinate voting shares and cash, is capped at US$5.00 per share—a threshold Aurora notes is lower than trading prices seen as recently as December 2025.

Management revealed that the two companies have been in intermittent dialogue since June 2026, though Aurora claims Curaleaf’s previous overtures lacked concrete financial detail. In response to the formal bid, Aurora has established a special committee of independent directors to evaluate the proposal with the assistance of legal and financial advisors, including Torys LLP and Fort Capital Partners. Shareholders have been advised to take no action until the board issues a formal recommendation, a process that must conclude within 15 days under securities regulations. The current offer is slated to remain open until at least December 1, 2026.